Post-DAA active surveillance for HCV-MZL (after SVR12)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-DAA-OBSERVATION-HCV-MZL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EASL-HCV-2023 SRC-ESMO-MZL-2024 |
Notes
Per ESMO MZL 2024 + EASL HCV 2023: after SVR12 confirmation following DAA, observe lymphoma response over 6-12 months. ~70% of HCV-associated MZL achieve hematologic response from antiviral therapy alone. Persistent / progressive lymphoma after 6-12 months observation routes to immunochemotherapy (rituximab or BR — REG-BR-STANDARD).
Used By
Indication
IND-CHRONIC-HCV-PREVENTION-OBSERVATION- IND-CHRONIC-HCV-PREVENTION-OBSERVATIONIND-HCV-MZL-POST-DAA-SURVEILLANCE- IND-HCV-MZL-POST-DAA-SURVEILLANCE